COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN TAIWAN

被引：1
|
作者：
Zou, D. [1 ]
Kendall, R. [1 ]
Lin, Q. [2 ]
Huang, Y. [2 ]
Tieng, J. [3 ]
Tseng, J. [3 ]
Sajosi, P. [4 ]
机构：
[1] ICON Plc, Vancouver, BC, Canada
[2] Kantar Hlth, Taipei, Taiwan
[3] Takeda Pharmaceut Taiwan, Taipei, Taiwan
[4] Takeda Pharmaceut Int AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.705
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE2
引用
收藏
页码：A811 / A811
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma
    Hux, Margaret
    Zou, Denise
    Ma, Esprit
    Sajosi, Peter
    Engstrom, Andreas
    Selby, Ross
    Benson, Eugene
    Teasell, Jeremy
    Richhariya, Akshara
    Briggs, Andrew
    Bonthapally, Vijayveer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [2] Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
    Liu, Jia
    Zheng, Lei
    Chuang, Ling-Hsiang
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 99 - 107
  • [3] THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN FRONTLINE SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN FRANCE
    Chaker, O.
    Nucit, A.
    Salvignol, O.
    Thoren, A. C.
    Cranmer, H.
    Coulibaly, C.
    Chevalier, J.
    Borget, I
    VALUE IN HEALTH, 2022, 25 (01) : S95 - S95
  • [4] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
    Paillassa, Jerome
    HEMATOLOGIE, 2018, 24 (01): : 19 - 21
  • [5] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [6] COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN TAIWAN
    Zou, D.
    Kendall, R.
    Lin, Q.
    Huang, Y.
    Tieng, J.
    Tseng, J.
    Sajosi, P.
    VALUE IN HEALTH, 2016, 19 (07) : A888 - A888
  • [7] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [8] Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Pro, Barbara
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle
    Connors, Joseph M.
    Fenton, Keenan
    Huebner, Dirk
    Pinelli, Juan M.
    Kennedy, Dana A.
    Shustov, Andrei
    BLOOD, 2017, 130 (25) : 2709 - 2717
  • [9] COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA
    Khachatryan, G. R.
    Fedyaev, D.
    Avxentyeva, M.
    Dombrovskiy, V. S.
    VALUE IN HEALTH, 2016, 19 (07) : A734 - A734
  • [10] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
12345